On November 1, 2021 CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody technology platform, reported that preclinical data for a conditionally activated interferon alpha-2b (IFN-a2b) will be presented at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 36th Annual Meeting (SITC 2021) taking place November 12-14, 2021, at the Walter E. Washington Convention Center in Washington, D.C (Press release, CytomX Therapeutics, NOV 1, 2021, View Source [SID1234593985]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Cytokines are powerful immune modulators with much potential for the treatment of cancer. We are excited to showcase the preclinical safety and anti-cancer activity of our conditionally activated interferon, highlighting the versatility and robust therapeutic potential of CytomX Probody-based biologics," stated Marcia P. Belvin, Ph.D., senior vice president and head of research of CytomX Therapeutics.

Details on CytomX’s poster presentation at SITC (Free SITC Whitepaper) 2021 are as follows:
Presentation Title: Conditional Cytokine Therapeutics for Tumor-Selective Biological Activity: Preclinical characterization of a dual-masked IFN-a2b
Abstract: 706